GIST
Oncology · 2007–2021
7decisions
3medicines
1carried consumer input
98individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ripretinib Treatment of advanced gastrointestinal stromal tumour (GIST) after failure of or intolerance to imatinib and sunitinib. | Mar 2021 | Not recommended | 98 individuals Life Raft Group |
| imatinib Change in pack size for imatinib tablets (100 mg and 400 mg) used in the treatment of patients with gastrointestinal stromal tumor (GIST) in both metastatic… | Mar 2015 | Not recommended | unclear |
| imatinib adjuvant treatment of a patient at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) | Mar 2012 | Not recommended | no section in document |
| imatinib adjuvant treatment for 12 months of a patient at high risk of recurrence following complete resection of primary gastrointestinal tumour (GIST) who meets… | Jul 2010 | Not recommended | no section in document |
| imatinib Adjuvant treatment for 12 months of adult patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Jul 2010 | Not recommended | no section in document |
| sunitinib malate The submission sought a Section 85 Authority Required listing for the initial and continuing treatment of gastrointestinal stromal tumour (GIST) after failure… | Jul 2009 | Recommended with restriction | no section in document |
| sunitinib malate Treatment of adult patients with metastatic or unresectable gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate due to resistance or… | Mar 2007 | Recommended | no section in document |
Who spoke
Life Raft Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.